Can manipulation of gut microbiota really be transformed into an intervention strategy for cardiovascular disease management?

被引:9
作者
Mehmood, Khalid [1 ,2 ]
Moin, Afrasim [1 ]
Hussain, Talib [3 ]
Rizvi, Syed Mohd Danish [1 ]
Gowda, D., V [4 ]
Shakil, Shazi [5 ,6 ]
Kamal, M. A. [5 ,7 ,8 ]
机构
[1] Univ Hail, Coll Pharm, Dept Pharmaceut, Hail, Saudi Arabia
[2] Abbottabad Univ Sci & Technol, Dept Pharm, Havelian, Pakistan
[3] Univ Hail, Coll Pharm, Dept Pharmacol & Toxicol, Hail, Saudi Arabia
[4] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmaceut, Mysuru, India
[5] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah, Saudi Arabia
[6] King Abdulaziz Univ, Ctr Excellence Genom Med Res, Jeddah, Saudi Arabia
[7] Enzymoics 7 Peterlee Pl, Hebersham, NSW 2770, Australia
[8] Educ Fdn, Novel Global Community, Hebersham, Australia
关键词
TRIMETHYLAMINE-N-OXIDE; SHARED DECISION-MAKING; HOST GENE-EXPRESSION; BILE-ACID; INTESTINAL MICROBIOTA; HEART-FAILURE; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; UNITED-STATES; RISK-FACTORS;
D O I
10.1007/s12223-021-00926-5
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recent advancement in manipulation techniques of gut microbiota either ex vivo or in situ has broadened its plausible applicability for treating various diseases including cardiovascular disease. Several reports suggested that altering gut microbiota composition is an effective way to deal with issues associated with managing cardiovascular diseases. However, actual translation of gut microbiota manipulation-based techniques into cardiovascular-therapeutic approach is still questionable. This review summarized the evidence on challenges, opportunities, recent development, and future prospects of gut microbiota manipulation for targeting cardiovascular diseases. Initially, issues associated with current cardiovascular diseases treatment strategy, association of gut microbiota with cardiovascular disease, and its influence on cardiovascular drugs were discussed, followed by applicability of gut microbiota manipulation as a cardiovascular disease intervention strategy along with its challenges and future prospects. Despite the fact that the gut microbiota is rugged, interventions like probiotics, prebiotics, synbiotics, fecal microbiota transplantation, fecal virome transplantation, antibiotics, diet changes, and exercises could manipulate it. Advanced techniques like administration of engineered bacteriophages and bacteria could also be employed. Intensive exploration revealed that if sufficiently controlled approach and proper monitoring were applied, gut microbiota could provide a compelling answer for cardiovascular therapy.
引用
收藏
页码:897 / 916
页数:20
相关论文
共 231 条
  • [101] Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats
    Khan, Tariq Jamal
    Ahmed, Youssri M.
    Zamzami, Mazin A.
    Mohamed, Saleh A.
    Khan, Imran
    Baothman, Othman A. S.
    Mehanna, Mohamed G.
    Yasir, Muhammad
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [102] In a Nutshell: Findings from the Bruneck Study
    Kiechl, Stefan
    Willeit, Johann
    [J]. GERONTOLOGY, 2019, 65 (01) : 9 - 19
  • [103] Gut Microbiota-Mediated Drug-Antibiotic Interactions
    Kim, Dong-Hyun
    [J]. DRUG METABOLISM AND DISPOSITION, 2015, 43 (10) : 1581 - 1589
  • [104] Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis
    Koeth, Robert A.
    Wang, Zeneng
    Levison, Bruce S.
    Buffa, Jennifer A.
    Org, Elin
    Sheehy, Brendan T.
    Britt, Earl B.
    Fu, Xiaoming
    Wu, Yuping
    Li, Lin
    Smith, Jonathan D.
    DiDonato, Joseph A.
    Chen, Jun
    Li, Hongzhe
    Wu, Gary D.
    Lewis, James D.
    Warrier, Manya
    Brown, J. Mark
    Krauss, Ronald M.
    Tang, W. H. Wilson
    Bushman, Frederic D.
    Lusis, Aldons J.
    Hazen, Stanley L.
    [J]. NATURE MEDICINE, 2013, 19 (05) : 576 - 585
  • [105] Fecal Microbiota Transfer May Increase Irritable Bowel Syndrome and Inflammatory Bowel Diseases-Associated Bacteria
    Konstantinov, Sergey R.
    Peppelenbosch, Maikel P.
    [J]. GASTROENTEROLOGY, 2013, 144 (04) : E19 - E20
  • [106] The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus
    Kootte, R. S.
    Vrieze, A.
    Holleman, F.
    Dallinga-Thie, G. M.
    Zoetendal, E. G.
    de Vos, W. M.
    Groen, A. K.
    Hoekstra, J. B. L.
    Stroes, E. S.
    Nieuwdorp, M.
    [J]. DIABETES OBESITY & METABOLISM, 2012, 14 (02) : 112 - 120
  • [107] Human oral, gut, and plaque microbiota in patients with atherosclerosis
    Koren, Omry
    Spor, Ayme
    Felin, Jenny
    Fak, Frida
    Stombaugh, Jesse
    Tremaroli, Valentina
    Behre, Carl Johan
    Knight, Rob
    Fagerberg, Bjorn
    Ley, Ruth E.
    Backhed, Fredrik
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 : 4592 - 4598
  • [108] Distinct roles for dietary lipids and Porphyromonas gingivalis infection on atherosclerosis progression and the gut microbiota
    Kramer, Carolyn D.
    Simas, Alexandra M.
    He, Xianbao
    Ingalls, Robin R.
    Weinberg, Ellen O.
    Genco, Caroline Attardo
    [J]. ANAEROBE, 2017, 45 : 19 - 30
  • [109] Intestinal Microbial Metabolites Are Linked to Severity of Myocardial Infarction in Rats
    Vy Lam
    Su, Jidong
    Hsu, Anna
    Gross, Garrett J.
    Salzman, Nita H.
    Baker, John E.
    [J]. PLOS ONE, 2016, 11 (08):
  • [110] Intestinal microbiota determine severity of myocardial infarction in rats
    Lam, Vy
    Su, Jidong
    Koprowski, Stacy
    Hsu, Anna
    Tweddell, James S.
    Rafiee, Parvaneh
    Gross, Garrett J.
    Salzman, Nita H.
    Baker, John E.
    [J]. FASEB JOURNAL, 2012, 26 (04) : 1727 - 1735